UA124019C2 - Спосіб лікування гострого пошкодження нирок - Google Patents

Спосіб лікування гострого пошкодження нирок Download PDF

Info

Publication number
UA124019C2
UA124019C2 UAA201904011A UAA201904011A UA124019C2 UA 124019 C2 UA124019 C2 UA 124019C2 UA A201904011 A UAA201904011 A UA A201904011A UA A201904011 A UAA201904011 A UA A201904011A UA 124019 C2 UA124019 C2 UA 124019C2
Authority
UA
Ukraine
Prior art keywords
compound
patient
kidney injury
acute kidney
acute
Prior art date
Application number
UAA201904011A
Other languages
English (en)
Ukrainian (uk)
Inventor
Бхарат Лагу
Майкл Патане
Еффі Тоззо
Эффи Тоззо
Скотт Тжаска
Original Assignee
Мітобрідж, Інк.
Митобридж, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мітобрідж, Інк., Митобридж, Инк. filed Critical Мітобрідж, Інк.
Publication of UA124019C2 publication Critical patent/UA124019C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
UAA201904011A 2016-10-05 2017-10-05 Спосіб лікування гострого пошкодження нирок UA124019C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
UA124019C2 true UA124019C2 (uk) 2021-07-07

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201904011A UA124019C2 (uk) 2016-10-05 2017-10-05 Спосіб лікування гострого пошкодження нирок

Country Status (33)

Country Link
US (1) US20210283116A1 (enExample)
EP (1) EP3522880B1 (enExample)
JP (1) JP7065839B2 (enExample)
KR (1) KR20190062502A (enExample)
CN (1) CN109789117B (enExample)
AU (1) AU2017340760B2 (enExample)
BR (1) BR112019005539A2 (enExample)
CA (1) CA3036723A1 (enExample)
CO (1) CO2019004561A2 (enExample)
CY (1) CY1124759T1 (enExample)
DK (1) DK3522880T3 (enExample)
ES (1) ES2859487T3 (enExample)
HR (1) HRP20210294T1 (enExample)
HU (1) HUE053557T2 (enExample)
IL (1) IL265749A (enExample)
JO (1) JOP20190056B1 (enExample)
LT (1) LT3522880T (enExample)
MA (1) MA46459B1 (enExample)
MD (1) MD3522880T2 (enExample)
MX (1) MX387518B (enExample)
MY (1) MY192385A (enExample)
PH (1) PH12019500725A1 (enExample)
PL (1) PL3522880T3 (enExample)
PT (1) PT3522880T (enExample)
RS (1) RS61573B1 (enExample)
RU (1) RU2753607C2 (enExample)
SG (1) SG11201901925RA (enExample)
SI (1) SI3522880T1 (enExample)
SM (1) SMT202100111T1 (enExample)
TW (1) TWI778982B (enExample)
UA (1) UA124019C2 (enExample)
WO (1) WO2018067857A1 (enExample)
ZA (1) ZA201901743B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392524B (es) 2015-10-07 2025-03-24 Salk Inst Biological Studies Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
BR112018069930B1 (pt) * 2016-04-13 2024-02-20 Mitobridge, Inc Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
EP3523283B1 (en) 2016-10-05 2021-06-09 Mitobridge, Inc. Crystalline and salt forms of ppar agonist compounds
US20220323416A1 (en) * 2019-07-19 2022-10-13 Vifor (International) Ag Ferroportin-Inhibitors For The Use In The Prevention And Treatment Of Kidney Injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20240019753A (ko) * 2021-03-08 2024-02-14 아비오닉스 파마 에스에이 간 질환을 치료하는 데 유용한 화합물
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028213T2 (en) * 2003-09-19 2016-12-28 Janssen Pharmaceutica Nv 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
BRPI0920170A2 (pt) * 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury
EP2981522A4 (en) * 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
EP2862574A1 (en) * 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
CN110007084B (zh) * 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX392524B (es) * 2015-10-07 2025-03-24 Salk Inst Biological Studies Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar

Also Published As

Publication number Publication date
JP7065839B2 (ja) 2022-05-12
MA46459B1 (fr) 2021-03-31
WO2018067857A1 (en) 2018-04-12
EP3522880A1 (en) 2019-08-14
US20210283116A1 (en) 2021-09-16
RU2019111421A (ru) 2020-11-06
SMT202100111T1 (it) 2021-05-07
AU2017340760A1 (en) 2019-03-21
CA3036723A1 (en) 2018-04-12
JOP20190056B1 (ar) 2022-03-15
SG11201901925RA (en) 2019-04-29
HRP20210294T1 (hr) 2021-04-16
RU2019111421A3 (enExample) 2021-02-05
PT3522880T (pt) 2021-02-22
PH12019500725A1 (en) 2019-08-05
CN109789117B (zh) 2022-08-23
MX2019003949A (es) 2019-06-10
PL3522880T3 (pl) 2021-08-23
TW201815391A (zh) 2018-05-01
KR20190062502A (ko) 2019-06-05
TWI778982B (zh) 2022-10-01
MX387518B (es) 2025-03-18
MD3522880T2 (ro) 2021-03-31
LT3522880T (lt) 2021-03-25
AU2017340760B2 (en) 2023-07-27
RS61573B1 (sr) 2021-04-29
HUE053557T2 (hu) 2021-07-28
CY1124759T1 (el) 2022-07-22
DK3522880T3 (en) 2021-01-18
JP2019533660A (ja) 2019-11-21
SI3522880T1 (sl) 2021-07-30
CN109789117A (zh) 2019-05-21
JOP20190056A1 (ar) 2019-03-24
RU2753607C2 (ru) 2021-08-18
ES2859487T3 (es) 2021-10-04
MY192385A (en) 2022-08-18
IL265749A (en) 2019-06-30
ZA201901743B (en) 2022-04-28
CO2019004561A2 (es) 2019-07-31
EP3522880B1 (en) 2020-12-02
MA46459A (fr) 2019-08-14
BR112019005539A2 (pt) 2019-06-18

Similar Documents

Publication Publication Date Title
RU2753607C2 (ru) Способы лечения острого повреждения почек
EP4126905B1 (en) Cyclophilin inhibitors and uses thereof
CN109748881A (zh) 胱硫醚-γ-裂合酶(CSE)抑制剂
EP1405638B1 (en) Pharmaceutical composition comprising quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate for treatment of interstitial cystitis and/or abacterial prostatitis
KR20020015382A (ko) 포스페이트 수송 억제제
US20160008336A1 (en) Hdac inhibitors for the treatment of traumatic brain injury
KR20220159474A (ko) 항미생물 화합물, 조성물, 및 그의 용도
RU2468015C2 (ru) Полиморфные формы деферасирокса (icl670a)
ES2210399T3 (es) Farmacos para profilaxis/tratamiento de las complicaciones de la diabetes.
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
PT2436672T (pt) Agente anti-choque compreendendo derivado de iaminotrifluorometilpiridina
US20250115596A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
TW201818939A (zh) 組合trh同功異質體及2-丙基辛酸而成之組成物以及2-丙基辛酸之藥學上所容許之鹽
CN113679728A (zh) 一种磺胺类化合物及其在制备治疗糖尿病和并发症药物中的应用
EP1408944B1 (en) Erucamide compounds for the treatment and prevention of disturbances of the secretory system
JP2010521524A (ja) N−ヒドロキシ−4−{5−[4−(5−イソプロピル−2−メチル−1,3−チアゾール−4−イル)フェノキシ]ペントキシ}ベンズアミジン2エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物
JP2026514991A (ja) 尿酸トランスポータアゴニスト化合物、医薬組成物、ならびにその調製方法および使用
EP1734031A1 (en) Novel 2-(alpha-n-pentanonyl)benzoetes, their preparation and use
CN113679725A (zh) 一种头孢类化合物及其在制备治疗糖尿病和并发症药物中的应用
WO2025179296A1 (en) Crystalline forms of nu-3 and uses thereof
CN118834186A (zh) 尿酸转运蛋白激动剂化合物、药物组合物及其制备方法和应用
HK40008682A (en) Methods of treating acute kidney injury
HK40008682B (en) Methods of treating acute kidney injury
US20070203233A1 (en) NOVEL 2-(alpha-N-PENTANONYL)BENZOATES, THEIR PREPARATION AND USE
JPH0676324B2 (ja) 糖ラクタムを含有する抗炎症剤